TMFBiologyFool

Brian Orelli

Somewhere between his graduate thesis on BRCA1, a gene that causes hereditary breast cancer, and his postdoctoral fellowship in DNA repair, Brian realized he enjoyed analyzing other people's data more than running his own experiments. Having gotten his first taste of how to analyze stocks from The Motley Fool many years prior, it was only fitting that he came full circle and started writing about biotech, pharmaceutical, and medical device companies for Fool.com. He also covers the health insurance industry to keep from going into binary-event overload. When not writing at The Motley Fool or trade journals like Nature Biotechnology and BioWorld, Brian can be found coaching soccer or hanging out at the beach in his hometown of San Diego.

TMFBiologyFool’s Activity

Thu Aug 28

NL

Article

TMFBiologyFool published an article 2:16 PM

Has Gilead Sciences, Inc.'s Star Drug Already Peaked?

Prescriptions of Gilead Sciences' hepatitis C drug Sovaldi peaked, but sales will pick up after the new combination product is approved.

Tue Aug 26

NL

Article

TMFBiologyFool published an article 5:56 PM

7 Things Regeneron Pharmaceuticals Inc.'s Management Wants You to Know

Highlights from Regeneron's conference call.

Mon Aug 25

NL

Article

TMFBiologyFool published an article 3:26 PM

Up 35% on Buyout: InterMune inc Investor Key Takeaways

FDA's rejection of InterMune's Esbriet hurt investors, but Roche clearly thinks the drug will be approved.

Wed Aug 20

NL

Article

TMFBiologyFool published an article 5:09 PM

3 Reasons Gilead Science, Inc.’s Stock Could Rise

Hepatitis C sales, a smart acquisition, and the potential for a dividend could all increase Gilead Sciences' stock price further.

Fri Aug 15

NL

Article

TMFBiologyFool published an article 3:24 PM

A Double Dose of Good News for Gilead Sciences, Inc.

Gilead Sciences gets a lawsuit win over Roche, keeping control of its hepatitis C drug Sovaldi. And the U.K.'s National Institute for Health and Care Excellence agrees to cover Sovaldi.

Wed Aug 13

NL

Article

TMFBiologyFool published an article 7:42 PM

Why Amgen, Inc.’s Kyprolis FOCUS Failure Is a Big Deal

European regulators are going to want to see survival data for Kyprolis.

NL

Article

TMFBiologyFool published an article 4:53 PM

5 Things MannKind Corp.'s Management Wants You to Know

Quotes from MannKind Corp.'s conference calls.

Mon Aug 11

NL

Article

TMFBiologyFool published an article 9:48 PM

Intercept Pharmaceuticals, Inc. Finally Releases FLINT Trial Data

Intercept Pharmaceuticals releases FLINT trial data in NASH patients.

NL

Article

TMFBiologyFool published an article 1:43 PM

MannKind Corporation Stock Signs Up Sanofi, Investors Conflicted

MannKind establishes a partnership with Sanofi to market its inhaled insulin Afrezza.

Fri Aug 8

NL

Article

TMFBiologyFool published an article 3:28 PM

Why Walgreen is Staying American and Paying Its Taxes

Walgreens buys Switzerland-based Alliance Boots, but decides not to move overseas in the process.

Thu Jul 24

NL

Article

TMFBiologyFool published an article 5:01 PM

Why Gilead Stock's Newest Drug Approval Isn't a Gamechanger

Gilead gains FDA approvela for its first cancer drug Zydelig, which will compete against Johnson & Johnson and Pharmacyclics' Imbruvica.

NL

Article

TMFBiologyFool published an article 3:48 PM

But Dad, I Was Only Doing My Fiduciary Duty

Mylan's CEO Heather Bresch is moving the company overseas; her dad, Senator Joe Manchin, isn't too happy about it.

Wed Jul 23

NL

Article

TMFBiologyFool published an article 6:12 PM

What Will Puma Biotechnology Inc's $700 Million Man Do Next?

A sale to Johnson & Johnson, Pfizer, Roche, or one of the other big pharmas seems like the most likely outcome for Puma Biotechnology Inc.

Tue Jul 22

NL

Article

TMFBiologyFool published an article 8:03 PM

Puma Biotechnology Inc's Overnight Triple is Just the Beginning

Pfizer gives Puma Biotechnology a gift, while Puma might be able to steal sales from Roche.

NL

Article

TMFBiologyFool published an article 5:01 PM

3 Things You Need to Watch on Gilead Sciences Inc. Earnings Call

Competition with AbbVie and Merck is important, but hepatitis C shouldn't be your sole focus.

Mon Jul 21

NL

Article

TMFBiologyFool published an article 4:07 PM

3 Quotes From Johnson & Johnson's Conference Call You Need to Read

Using cash from a divestiture, competition from Gilead and AbbVie, and a discussion of biosimilars.

NL

Article

TMFBiologyFool published an article 2:01 PM

Yellen Hates Biotech Stocks! Should You?

Are big biotechs -- Amgen, Biogen Idec, Gilead Sciences, and Celgene -- really overvalued, or is the Fed chairwoman looking at smaller companies?

Tue Jul 15

NL

Article

TMFBiologyFool published an article 5:34 PM

Time to Fall Back in Love With Exelixis Inc.?

Good news from Exelixis' partner Roche, but we don't know if the trial data is good enough to beat GlaxoSmithKline's competing regimen.

Mon Jul 14

NL

Article

TMFBiologyFool published an article 1:45 PM

Arena Pharmaceuticals Inc. Still Down After CEO's Sale

It says something about the short-term prospects for Arena Pharmaceuticals. And competitors, Orexigen and VIVUS, for that matter.

Thu Jul 10

NL

Article

TMFBiologyFool published an article 3:47 PM

3 Reasons Not to Worry About Sarepta Therapeutics Inc.

Sarepta Therapeutics fell on its 144-week data, but the approvability -- based on trials run by PTC Therapeutics and Prosensa -- is likely to be based on 48-week data.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 95.87
Player Rank 3098 out of 75032
Score 1303.39
Score Change Today 0
Accuracy 66.35%
Active Picks 73
Total Picks 213
Best Pick MYL (+250.17)
Worst Pick INCY (-441.66)
Average Score per Pick 6.12
Charms Earned 8
Highest Rated Favorite zzlangerhans
Go to TMFBiologyFool’s CAPS page

Boards Stats & Trivia

Three stars, 500 posts CAPS All Star
Board Posts 928
Recs Received 982
People who have rec'd these posts 380
Recs to Posts Ratio (last 30 days) N/A
Threads Started 90
Threads Started Percentage 9.70 %
Most Frequent Board Buying or Selling a Home
Very First Post Re: How many is enough? (6/6/2001)
Percentage of Posts Rec'd 48.17 %
Show TMFBiologyFool’s 10 Latest Posts